Healthcare Industry News:  benign prostatic hyperplasia 

Devices Urology

 News Release - May 19, 2006

Boston Scientific and Lumenis to Market Trimedyne's New Fiber

IRVINE, Calif.--(HSMN NewsFeed)--May 19, 2006--Trimedyne, Inc. (OTCBB:TMED ) today announced it has entered into an agreement with Lumenis, Ltd. under which Trimedyne will manufacture the DuraMax(TM) Side Firing Laser Fiber exclusively for Lumenis. The DuraMax Fiber will be marketed by Boston Scientific Corporation (NYSE:BSX ) under the Boston Scientific label in the United States. The new device will be used in conjunction with Lumenis' VersaPulseŽ PowerSuite(TM) Holmium Laser for holmium laser ablation of the prostate, known as HoLAP. HoLAP is a rapidly growing, minimally invasive technique for the treatment of benign prostatic hyperplasia, or BPH. Sometimes referred to as enlarged prostate, BPH is a condition affecting an estimated 50% of men over age 50 and up to 90% of men over 80 years of age.

In the U.S. alone almost 200,000 men with BPH are treated each year, many with an invasive surgical procedure known as a TURP or Transurethral Resection of the Prostate. With TURP, prostate tissue is cut into small pieces with an electrically heated wire loop, and the pieces are then flushed out with irrigating fluid. Patients treated with TURP commonly stay in the hospital 1-3 days, take longer than a week to recuperate, and experience bleeding during and after the procedure, resulting in up to 10% requiring a blood transfusion.

With HoLAP, prostate tissue is vaporized with holmium laser energy. This virtually bloodless procedure provides almost immediate symptom relief with fewer complications than typically seen with TURP. Patients are typically treated on an outpatient basis and quickly return to normal activities.

"Our new, patented Fiber is exciting because it's designed to vaporize soft tissue faster and last longer than other fibers on the market today," commented Glenn D. Yeik, Trimedyne President. "I'm very pleased to have well-respected industry leaders like Boston Scientific and Lumenis promote our new Fiber," he added.

Based on laboratory testing on animal soft tissue, Trimedyne's new Fiber vaporizes an average of 3 to 4 grams of soft tissue per minute and lasts longer than required to treat a normal size prostate using 80 to 100 watts of holmium laser energy. A faster vaporization rate reduces both physician and operating room time, and increased durability means that one device should be sufficient to treat even a large prostate.

"This new single use fiber is truly a breakthrough," stated Avner Raz, Lumenis President and CEO. "This technologically advanced fiber optic device will provide clinical advantages that are consistent with our commitment to bringing physicians leading edge technology. We intend to pursue an aggressive marketing and sales strategy to promote the benefits of HoLAP and the added efficiency that the DuraMax Fiber will provide to urologists around the world."

Lumenis will market the DuraMax Fiber under its own label through its sales and distributor organizations in countries other than the United States. Trimedyne's new device was cleared for sale by the FDA earlier this year.

Lumenis and Boston Scientific expect the marketing of the DuraMax Fiber will commence in the United States and elsewhere throughout the world in the last quarter of 2006.

About Boston Scientific: Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit www.bostonscientific.com

About Lumenis: Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems, including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto www.lumenis.com

About Trimedyne: Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery. Trimedyne has an extensive portfolio of patents covering side-firing laser technologies. To review current press releases, product, financial and other information, visit Trimedyne's website, www.trimedyne.com.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports. There is no assurance any new products can be successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.


Source: Trimedyne

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.